Solano County Substance Use Symposium Brings Drug Treatment Community Together to Reduce Overdoses
ClosedLoop Selected to Participate in AWS Healthcare Accelerator for Health Equity
AUSTIN, Texas - August 31, 2022 - (Newswire.com)
ClosedLoop today announced it has been selected to participate in the AWS Healthcare Accelerator for Health Equity, a technical, business, and mentorship program for startups seeking to use AWS to increase access to health services, reduce disparities by addressing social determinants of health (SDoH), and/or use data to promote equitable and inclusive systems of care. This opportunity will support ClosedLoop's efforts to improve health outcomes and health equity by incorporating SDoH into accurate, explainable, and actionable predictions of individual-level health risks.
The four-week AWS Healthcare Accelerator curriculum provides hands-on AWS Cloud and technical training, mentorship, coaching, and business support. As one of 10 companies chosen for this opportunity, ClosedLoop will receive up to $25,000 in AWS Promotional credits, AWS training and support, mentorship, and additional business development resources including opportunities to speak with healthcare-savvy venture investors.
ClosedLoop was recently recognized by KLAS Research as the 2022 Best in KLAS Leader for Healthcare AI: Data Science Solutions. In 2021, the company was named the "1st Place Winner" among 300 entrants in the Artificial Intelligence (AI) Health Outcomes Challenge and awarded a $1.6 million prize by CMS. ClosedLoop won the CMS Challenge in part due to its effectiveness at addressing hidden algorithmic biases that, when left unchecked, can make health disparities worse.
Improving health equity is a core strategic objective of transformative value-based care programs. Being part of the AWS Healthcare Accelerator will enable ClosedLoop to share its healthcare-focused AI/ML platform and content to healthcare organizations throughout the AWS and KidsX networks that are interested in using SDoH data to identify and reduce health disparities.
"Health disparities cost the United States $320 billion each year, so reducing them is both a moral and financial imperative," said Andrew Eye, CEO and co-founder at ClosedLoop. "By leveraging the scalability and reliability of AWS service offerings, the ClosedLoop platform will help healthcare organizations leverage vast amounts of data from diverse sources to identify individuals with the most impactful health-related social needs."
"AWS looks forward to collaborating with this impressive group of startups who are helping reduce health disparities with thoughtful and inspiring solutions," said Jeff Kratz, general manager of Worldwide Public Sector Partners at AWS. "We believe that by working together, we can help them harness the power of the cloud to make access to healthcare more equitable."
For more information on the AWS Healthcare Accelerator, visit https://www.kidsx.health/aws-accelerator/.
About ClosedLoop
ClosedLoop is healthcare's data science platform. We make it easy for healthcare organizations to use AI to improve outcomes and reduce costs. Purpose-built and dedicated to healthcare, ClosedLoop combines an intuitive end-to-end machine learning platform with a comprehensive library of healthcare-specific features and model templates. Customers use ClosedLoop's Explainable AI to drive clinical excellence, operational efficiency, value-based contracts, and enhanced revenue. Winner of the CMS AI Health Outcomes Challenge and named Best in KLAS for Healthcare AI: Data Science Solutions in 2022, ClosedLoop is headquartered in Austin, Texas. For more information on ClosedLoop, visit www.closedloop.ai.
Contact
Scott Davis
[email protected]
608-235-3244
Press Release Service by Newswire.com
Original Source: ClosedLoop Selected to Participate in AWS Healthcare Accelerator for Health Equity
Lena Instruments & Flare Network Reimagine Crowdfunding With CloudFunding® Launchpad
Advantage Healthcare Consulting Partners With NuParadigm Products to Deliver Cost Savings and Best-in-Class Product...
Sun West’s CEO, Pavan Agarwal Set to Present at Stanford University’s – the Science...
Sun West Mortgage Company, Inc. (www.swmc.com) CEO Pavan Agarwal is set to attend and speak at this year's The Science of Blockchain Conference 2022 (SBC '22). Co-organized by the Stanford Center for Blockchain Research (CBR) and IC3, the conference will be held at Stanford University, Aug. 29-31, 2022.
Since their founding in 1980, Sun West Mortgage Company, Inc. ("Sun West"), a national leader in Mortgage Originations and Serving, has been committed to core values of people, experience, technology, and product. Now, after years of development, Sun West has recently launched the newest iteration of their proprietary AI platform, MORGAN™, which is redefining blockchain technology, banking tech and the mortgage industry.
Powered by Sun West's sister technology company Celligence (www.celligence.com) and the mass adoption and introduction of blockchain innovation, MORGAN™ reverses what we know of the traditional home buying processes. Sun West's novel application of open ledger technology is ground-breaking and truly advances how real estate sales are transacted and completed.
Pavan Agarwal, founder and CEO of Sun West & Celligence, will attend this year's SBC'22 conference and take to the stage to detail just how Sun West's MORGAN™ employs blockchain technology to convert mortgages into NFTs, thereby removing traditional home buying hurdles, especially for underserved communities.
Marking how the company's latest advanced technology loan product seeks to reach independent, truthful lending and larger equality in the real estate market with built-in blockchain technology, Agarwal will showcase how MORGAN™ is truly one-of-its-kind, and nothing like you've seen before - you will not want to miss it!
Now in its fifth year, The Science of Blockchain Conference focuses on technical innovations in the blockchain ecosystem and brings together researchers and practitioners working in the space. The event will showcase the application of cryptography, decentralized protocols, formal methods and empirical analysis to improve the security and scalability of blockchain deployments.
The conference hosts affiliated workshops related to cryptography, distributed systems and secure computing by fostering collaboration among practitioners and researchers working on blockchain technology. It welcomes the very best in the world of blockchain and crypto space to be program speakers. The full speaker program can be found here.
Mr Agarwal explained "The Framers of the US Constitution understood that land ownership is the path to true political and economic freedom. Although much work is still to be done to achieve universal fair housing & lending, the American system has intentionally distributed property ownership across a broad section of the population. My implementation of the blockchain in Morgan™ is a decentralized platform that increases the accessibility, agility, and transparency of trading real estate amongst Americans and strengthens our Republic. Real estate ownership is deliberately distributed, and I have created Morgan™ so that control of property rights can never fall into the hands of the few."
The conference is free to attend in-person and remotely via live-stream. For full event information visit https://cbr.stanford.edu/sbc22.
About Sun West Mortgage Company (NMLS ID 3277) -
Visit www.swmc.com/tru-terms for TRU Approval® terms and conditions. For licensing information, go to: www.nmlsconsumeraccess.org. Visit http://www.swmc.com/disclaimer for the full list of license information. Please refer to https://www.swmc.com/TXdis to view Texas Complaint Notice and Servicing Disclosure. In all jurisdictions, the principal (main) licensed location of Sun West Mortgage Company, Inc. is 6131 Orangethorpe Avenue, Suite 500, Buena Park, CA 90620, Phone: (800) 453-7884.
Press Release Service by Newswire.com
Original Source: Sun West's CEO, Pavan Agarwal Set to Present at Stanford University's - the Science of Blockchain Conference 2022
BankLine and B4U Bring Crypto to Cannabis
Eyenovia’s Novel Optejet® Dispenser Puts People’s Eyes First
NEW YORK - August 30, 2022 - (Newswire.com)
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, brings human-centric design to ophthalmology with its novel Optejet® dispenser.
Traditional eye drops normally overdose the patient's eye with medication and preservatives. Eyenovia's easy-to-use, novel Optejet® dispenser administers precisely 8µL of medication to the eye, effectively treating the patient's condition while creating a more gentle dosing experience.
"The unique delivery mechanism of the Optejet® will fundamentally change how we think about eye medication," said Michael Rowe, CEO of Eyenovia. "Right now, traditional eye drops can result in significant dose-related side effects for the treatment of chronic illnesses like glaucoma. The Optejet® dispenser is designed for patients to experience easier administration and fewer side effects with similar efficacy."
The Optejet® dispenser administers ophthalmic solutions horizontally using Eyenovia's proprietary Microdose Array Print (MAP™) technology. The system functions similar to an inkjet printer, delivering accurate microdoses through a precision spray. Traditional eye drops deliver four to five times larger volume than the human eye can actually hold, which causes eye drops to roll down the face and overdose the eye with preservatives.
Poor delivery of eye drops is more than an inconvenience; it can prevent patients from using necessary medication because of the side effects. For example, with medication to help dilate the pupils for eye exams, up to 23% of patients experienced stinging and burning with the eye drops, causing patients to forgo eye exams. In Eyenovia studies, less than 1% of patients experienced stinging and burning.
"Medications only work if patients take them, and with the Optejet, we have designed a way for patients to benefit from an easy-to-use, appropriate, lower dose spray that results in similar efficacy. We're excited for physicians and providers to be able to offer this revolutionary technology in the near future to patients who deserve a more positive experience," said Rowe.
Eyenovia's first marketed invention is expected to be MydCombi™, a first-in-class drug-device combination microdose for in-office pupil dilation. This potentially will help save physician's chair time, eliminating the traditional three eyedrops used for a patient's eye exam. Other exciting innovations in the Eyenovia pipeline include MicroLine (for the treatment of Presbyopia) and MicroPine (for the treatment of Myopia).
For more information, visit eyenovia.com.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia, and myopia progression. For more information, visit www.eyenovia.com.
Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents that we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws. Eyenovia does not undertake any obligation to update any forward-looking statements.
Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
[email protected]
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
[email protected]
(646) 751-4363
Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
[email protected]
Press Release Service by Newswire.com
Original Source: Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First
MadgeTech’s HiTemp140-FP Expands Temperature Range
MadgeTech, a leading data logger manufacturer, announces the expanded temperature range of the HiTemp140-FP data logger with the ability to monitor and record temperatures from -200 °C to +260 °C (-328 °F to +500 °F).
Designed for high-temperature applications, including autoclave validation, food processing, and mapping studies, the HiTemp140-FP is made of stainless steel and features an RTD sensor with PFA insulated cable, available in lengths from six to 72 inches. All probe lengths are available with either a stainless-steel tip for easy placement into vials or test tubes, or a bare version for use with accessories such as the CF200 for canning application or the MicroDisc for surface temperature monitoring.
The expanded temperature range now enables the HiTemp140-FP to monitor temperatures as low as -200 °C (-328 °F), making it a multi-use solution for both high and low temperatures. The body of the HiTemp140 can withstand temperatures from -40 °C to +140 °C (-40 °F to +284 °F)
For more information on the HiTemp140-FP, please contact MadgeTech at [email protected].
About MadgeTech
Headquartered in Warner, New Hampshire, MadgeTech has over 25 years of experience in the engineering and manufacturing of data loggers. As an ISO 9001 company, MadgeTech is built on the founding principles of quality, customer satisfaction, and consistent improvement. MadgeTech offers a range of data loggers capable of measuring over 10 different parameters and features an in-house ISO 17025 certified calibration laboratory.
Press Release Service by Newswire.com
Original Source: MadgeTech's HiTemp140-FP Expands Temperature Range
Novant Health Improves Patient Collection Rates and Satisfaction Through Partnership With Cedar
Novant Health, one of the largest healthcare systems in the Southeast, has significantly improved its patient financial experience by partnering with Cedar, an enterprise healthcare engagement platform that improves the end-to-end consumer financial journey. By investing in Cedar Pay, Cedar's post-visit billing and payment platform, Novant Health continues to lead the way when it comes to bringing digital innovation to the revenue cycle.
For years, Novant Health had worked to modernize their revenue cycle organization, leaning on mail, email and EHR communications to reach patients. While these initiatives drove incremental improvements, the health system identified two key opportunities in 2019 to truly enable a more consumer-centric experience for their patients:
-
Combining Novant Health's acute and ambulatory services into a single billing experience. While the organization had tried to combine physician and facility billing for years, they had always been met with pushback from vendors or complex EHR upgrades that could fundamentally break their existing processes.
- Making bill payment a low friction, easy to navigate experience for both patients and team members. Novant Health wanted to help patients understand how their payments work and how their insurance benefits applied. In order to do so, they needed to personalize the experience, using mobile technology that consumers were already familiar with.
To address these challenges, Novant Health invested in Cedar Pay. Cedar Pay delivers personalized billing through outreach, messaging and bill resolution based on a variety of unique factors and preferences. The platform is fully integrated with Novant Health's existing Epic EHR system across both hospital billing and physician billing.
As a result of their implementation of Cedar Pay, Novant Health has seen a material rise in collections over a 12-month period, amounting to tens of millions of dollars, as well as:
- 90% patient satisfaction score
- 87% of collections now completely self-serviced
- 43% drop in days to collect
"Investing in a consumer engagement platform like Cedar is something we had wanted to do for a long time as part of our digital transformation strategy—we wanted to create a singular financial experience that allows our patients to pay with the technology we keep in our pockets," said Geoff Gardner, senior vice president of Finance at Novant Health. "Cedar has been a great partner to us in our commitment to delivering a remarkable healthcare experience to our community; the results truly speak for themselves, as we have been able to increase collections while also improving patient satisfaction."
"At Cedar, we know that engaged, happy patients lead to better outcomes, and the best way to improve patient satisfaction is by implementing consumer-friendly technology," said Florian Otto, CEO and co-founder of Cedar. "It's been a privilege working with such an innovative health system like Novant Health, and we look forward to continuing our partnership and continuing to impact the lives of their patients."
To learn more about how Novant Health has seen a 9x ROI through its strategic partnership with Cedar, read the full case study here.
About Cedar
Cedar is committed to improving the healthcare billing experience for all. With an innovative platform that connects providers and payers, Cedar empowers healthcare consumers with a personalized journey—all powered by data science and interactive design. For Cedar clients, this leads to increased collections, more efficient operations and greater consumer loyalty. To learn more about why leading U.S. healthcare organizations trust Cedar to manage the end-to-end consumer experience from pre-registration to post-visit billing, visit www.cedar.com and join us on LinkedIn, Twitter, Facebook and YouTube.
About Novant Health
Novant Health is an integrated network of physician clinics, outpatient facilities and hospitals that delivers a seamless and convenient healthcare experience to communities in North Carolina, South Carolina, Virginia and Georgia. The Novant Health network consists of more than 1,800 physicians and over 35,000 employees who provide care at nearly 800 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. In 2021, Novant Health was the highest-ranking healthcare system in North Carolina to be included on Forbes' Best Employers for Diversity list. Diversity MBA Magazine ranked Novant Health first in the nation on its 2021 list of "Best Places for Women & Diverse Managers to Work." In 2020, Novant Health provided more than $1.02 billion in community benefit, including financial assistance and services.
For more information, please visit our website at NovantHealth.org. You can also follow us on Twitter and Facebook.
Contact
For Cedar
Jenny Fiegoli
PR & Communications Manager
[email protected]
For Novant Health
Novant Health media relations
844-536-3288 (this number does not accept text messages)
[email protected]
Press Release Service by Newswire.com
Original Source: Novant Health Improves Patient Collection Rates and Satisfaction Through Partnership With Cedar
